Skip to main content
. Author manuscript; available in PMC: 2021 Apr 19.
Published in final edited form as: Semin Reprod Med. 2020 Oct 26;38(2-03):168–178. doi: 10.1055/s-0040-1718741

Figure 1.

Figure 1.

The role of aberrant β-catenin activation in EMT and adenomyosis. (A) Representative immunostaining images showing the levels of β-catenin (a-c), E-cadherin (d-f), COUP-TFII (g-i), and E-cadherin/vimentin (red/green; j-l) in endometrium from control women (a, d, g, and j) and eutopic endometrium (b, e, h, and k) and adenomyosis lesions (c, f, i, and l) from women with adenomyosis. (B) Representative immunostaining images showing the levels of β-catenin (a-c), E-cadherin (d-f), COUP-TFII (g-i), and E-cadherin/vimentin (red/green; j-l) in endometrium from control mice (a, d, g, and j) and eutopic endometrium (b, e, h, and k) and adenomyosis lesions (c, f, i, and l) from mice with β-catenin activation (Pgrcre/+Ctnnb1f(ex3)/+).